Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients with Early Breast Cancer who are Ineligible for Treatment with trastuzumab as defined by IHC status
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Females aged 18 or older Early stage breast cancer and planned surgery
Ineligible for Trastuzumab (Herceptin) treatment as per local guidelines
World health Organisation performance status of 0 to 1 Tumour size amenable to obtaining adequate biopsies pre dosing.
You may not be if
Eligible for Trastuzumab (Herceptin) Treatment Known sensitivity to AZD8931, its excipients or drugs in its class;
Including oral tyrosine kinase inhibitors History of eye conditions e.g. previous injury within 3 months or clinically significant eye disease
Concurrent malignancy Unable to discontinue medication or herbal supplement known to inhibit CYP3A4 or CYP2D6
Clareo Health | Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment
